



### 4Q20 M&A Activity

- Despite continued pressures from Covid-19 global M&A activity bounced back towards the end of 2020, with near record volume across a number of geographies and sectors. Looking ahead to 2021, volumes are expected to remain steady as delayed deals begin to close and vaccines roll out. Access to cheap capital and record levels of dry powder should also motivate corporate and private buyers to pursue deals in 2021.
- On December 17, 2020, Novartis AG agreed to buy Cadent Therapeutics, a U.S. developer of treatments for cognitive and mood disorders, for as much as \$770 million. Cadent is developing a drug for schizophrenia, and it has an alliance already with Novartis on a product for treatment-resistant depression.
- On December 6, 2020, Endo International plc announced that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for \$88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately \$660 million.
- On November 18, 2020, Bristol Myers Squibb has completed the acquisition of clinical-stage biopharmaceutical company MyoKardia for \$13.1 billion. The deal provides BMS with MyoKardia's mavacamten, which is a potential first-in-class cardiovascular medicine to treat obstructive hypertrophic cardiomyopathy.
- On October 1, 2020, Johnson & Johnson announced it successfully completed the acquisition of Momenta Pharmaceuticals, Inc., a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately \$6.5 billion.


### Trend in Industry EBITDA Multiples<sup>1</sup>



### Trends in Revenue Growth and EBITDA Margins<sup>1</sup>




### Relative Stock Price Returns<sup>2</sup>



<sup>1</sup> Calculated using aggregated data for JNJ, PFE, Novartis, MRK, ABBV, AMGN, Novo, GSK, Sanofi, LLY, GILD, BMY, LSE:AZN, AGN, MYL, TEVA, BHC, MNK, PRGO, ENDP, AMRX.

<sup>2</sup> The Pharmaceutical Industry is a custom, equal-weighted index constructed with the aforementioned companies.

### Purchase Price Allocation (PPA) % from Recent Transactions



### Notable M&A Deals



On December 8, 2020, Novo Nordisk has completed its \$1.8-billion acquisition of Emisphere Technologies, a Roseland, New Jersey-based drug-delivery company. As a result of the completion of the merger, Emisphere has become a wholly owned subsidiary of Novo Nordisk. The acquisition was announced early November 2020. Novo Nordisk has acquired all outstanding shares of Emisphere for \$1.35 billion.



On December 18, 2020, Merck & Co. acquired VelosBio for \$2.75 billion cash in a deal that bolsters the buyer's growing oncology pipeline with a clinical-phase antibody-drug conjugate being evaluated for solid tumors and blood-based cancers. VelosBio last month dosed its first patient in a Phase II trial of VLS-101, designed to evaluate the ADC in patients with solid tumors that include triple-negative breast cancer hormone receptor-positive and/or HER2-positive breast cancer, and non-squamous non-small-cell lung cancer.



On December 15, 2020, Eli Lilly and Company and Prevalil Therapeutics Inc. announced a definitive agreement for Lilly to acquire Prevalil for a total consideration of up to \$26.50 per share in cash, or an aggregate of approximately \$1.04 billion. The acquisition will establish a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program.